News | April 14, 2009

AHA Funds Three Research Centers to Study Generation of Cardiac Muscle Cells

April 14, 2009 - Three research centers have been awarded funding from the American Heart Association, with support from the Jon Holden DeHaan Foundation, to study the development and mechanisms of generating new cardiac muscle cells.

The centers will be conducting studies over the next four years to ultimately determine how regeneration of those cells can help improve outcomes for heart attack and heart failure patients.

The grants, totaling $6 million, have been awarded to the following facilities, which will each become home to an American Heart Association-Jon Holden DeHaan Foundation Cardiac Myogenesis Research Center:

-- University of Pennsylvania, Philadelphia, PA. - Center Director:
Jonathan Epstein, M.D.
-- University of Texas Southwestern Medical Center, Dallas, TX -
Center Director: Eric Olson, Ph.D.
-- University of Minnesota, Minneapolis, MN - Center Director: Doris
Taylor, Ph.D.

Each center will undertake a number of basic science research projects specifically looking at cardiac myocytes, or heart cell muscles, to learn more about how those cells biologically develop, integrate and work. Ideally, findings from this research will lead to new ways for treating various forms of heart disease, including heart attacks, congenital heart disease and heart failure.

Some of the research will focus on developing methods to identify stems cells from the heart or other organs, such as bone marrow, to give back to the patient in a way that will sustain long-lasting recovery of cardiac function. The research will build the foundation for future use of adult stem cells for regenerating and repairing heart muscle, as well as for developing new therapies and drugs in the fight against heart disease.

Thee awards are effective April 1, 2009, and will be funded through March 31, 2012.

For more information: www.americanheart.org

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init